Clinical Trial Update: A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating pyrotinib plus capecitabine with stereotactic radiotherapy in HER2-positive metastatic breast cancer with brain metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Jiangxi Provincial Cancer Hospital | Conditions: HER2-positive Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN